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Background: Virtually all low- and middle-income countries are dependent on the World Health Organization’s
Expanded Program on Immunization for delivery of vaccines to children. The Expanded Program on Immunization
delivers routine immunization services from health facilities free of charge. Understanding interventions for
improving immunization coverage remains key in achieving universal childhood immunization.
Methods: We will conduct a systematic review that aims to assess the effectiveness of the full range of potential
interventions to improve routine immunization coverage in children in low- and middle-income countries. We will
include intervention studies, as well as observational studies. We will search the Cochrane Database of Systematic
Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, electronic databases
for eligible studies published by 31 August 2013. At least two authors will independently screen search outputs,
select studies, extract data and assess the risk of bias (using separate criteria for interventions and observational
studies); resolving any disagreements by discussion and consensus. The use of logic models and the Cochrane
Complexity Matrix will be explored in order to better understand and contextualize studies. We will express the
result of each study as a risk ratio with its corresponding 95% confidence intervals for dichotomous data, or mean
difference with its standard deviation for continuous data. We will conduct meta-analysis for the same type of
participants, interventions, study designs, and outcome measures where homogeneity of data allows. Use of harvest
plots may be explored as an alternative. Heterogeneity will be assessed using the χ2 test of heterogeneity, and
quantified using the I2 statistic. This protocol has not been registered with PROSPERO.
Discussion: This review will allow us to document evidence across a broad range of intervention types for
improving routine immunization coverage in children and also distinguish between those that are well supported
by evidence (to direct policy recommendations) and those that are not well supported (to direct research agenda).
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Table 1 Vaccines recommended for children by the World
Health Organization (WHO) typically given in low- and
middle-income countries (LMICs)a
Vaccine Doses Age Minimum interval
BCG 1 Birth or soon after Not applicable
OPV 4 Birth, 6, 10, 14
weeks
4 weeks
DTP 3 6, 10, 14 weeks 4 weeks
HepBb 3/4 Birth, 6, 10, 14
weeks
4 weeks
Hib 3 6, 10, 14 weeks 4 weeks
PCV 3 6, 10, 14 weeks 4 weeks
RVc 2/3 6, 10, 14 weeks 4 weeks
Measles 1 9 months Not applicable
Rubellad 1 9 or 12 months Not applicable
Yellow fever 1 9 months Not applicable
Vitamin A 2 9, 15 months 6 months
HPVe 3 9 to 13 years Variable
Meningococcaf 1/2 >9 months Variable
Japanese encephalitisg 1/2 9 to 12 months 4 weeks
aFull list of recommended vaccines here: http://www.who.int/immunization/
policy/Immunization_routine_table2.pdf.
bSome countries have a policy of giving a birth dose of the hepatitis
B vaccine.
cThere are two types of licensed rotavirus vaccines, Rotateq and Rotarix.
Rotarix is given in two doses, while a full series of Rotateq vaccination consists
of three doses. The first dose of the rotavirus vaccine should be administered
between 6 and 14 weeks. The maximum age for administering the last dose of
the vaccine should be 32 weeks.
dMinimum age for giving rubella is 6 months.
eThere are two types of licensed HPV vaccines. The quadrivalent vaccine is
given between 9 to 13 years with a 4-week minimum interval between the
first and second dose, and a minimum of 12 weeks between the second and
third dose. The bivalent vaccine is given between 10 to 13 years with a max-
imum of 2.5 months between the first and second dose.
fThere are three meningococcal vaccines available: Men A conjugate, one dose
given between 1 and 29 years; Men C conjugate, two doses given between 2
and 11 months with a minimal interval of 8 weeks between first and second
dose, or one dose given >12 years; quadrivalent conjugate, two doses
between 9 and 23 months, with 12 weeks between the first and second dose,
or one dose given at >2 years.
gThere are two vaccines available: the mouse-brain-derived vaccine, two doses
given at 1 year, with 4 weeks between first and second dose; and the live at-
tenuated vaccine, one dose given between 9 and 12 months.
BCG Bacille Calmette-Guérin, DTP diphtheria-tetanus-pertussis vaccine, HepB
hepatitis B vaccine, Hib Haemophilus influenzae type b vaccine, HPV human
papilloma virus, PCV pneumococcal conjugate vaccine, OPV oral polio vaccine,
RV rotavirus vaccine.
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Following the successful eradication of smallpox, the
World Health Organization (WHO) launched the Ex-
panded Program on Immunization (EPI) in 1974 with
the hope of achieving 80% coverage of children less than
1 year of age with vaccines against six major causes of
death among children (measles, diphtheria, tetanus,
polio, tuberculosis and pertussis) by 1990 [1,2]. Virtually
all low- and middle-income countries (LMICs) are
dependent on EPI for delivery of vaccines to children.
EPI delivers routine immunization services from health
facilities free of charge. ‘Routine immunization’ services
rely on residents going to fixed sites to receive a service
that is offered regularly throughout the year. Routine
immunization services may also include mobile teams,
which take services at regular intervals to populations
without nearby health centers; and ‘outreach activities’
which reach out regularly to the community to provide a
service or retrieve defaulters [3].
While routine immunization schedules may vary by
country, the vaccines shown in Table 1 are recom-
mended by WHO. Some vaccines such as those against
measles, diphtheria, tetanus and pertussis are recom-
mended for all children; others such as those against yel-
low fever and Japanese encephalitis are recommended
only for children residing in areas where such diseases
are endemic; and others such as cholera and typhoid
vaccines are recommended for children in some high-
risk populations. In addition, some vaccines are given as
combination vaccines such as the pentavalent vaccine
against diphtheria, tetanus, pertussis, hepatitis B (Hep B)
and Haemophilus influenzae type b (Hib).
Coverage with three doses of the diphtheria-tetanus-
pertussis vaccine (DTP3) by 1 year of age is widely ac-
cepted as a proxy for measuring overall EPI performance.
In 2011, global DTP3 coverage reached 83%. However,
Africa lagged behind and coverage reached only 74%
[4]. Poor vaccination coverage in LMICs has been attrib-
uted to several reasons associated with immunization sys-
tems, parental attitude and knowledge, communication
and information, and family characteristics [5-8]. There-
fore, interventions for improving childhood immunization
coverage may target parents and caregivers in the commu-
nity, the service provider, the health system, or a unique
combination of any of these. Interventions for improv-
ing childhood immunization coverage in LMICs have
recently been assessed in a systematic review [9]. How-
ever, only randomized controlled trials (RCTs), non-
randomized controlled trials (NRCTs) and interrupted
time series (ITS) studies were eligible for inclusion in
the review, and only six studies met the inclusion
criteria. As not all health systems interventions lend
themselves to being investigated through RCTs, it is
important to look beyond these study designs of highinternal validity to identify other interventions of poten-
tial relevance.Objectives
We aim to assess the effectiveness of the full range of
potential interventions to improve routine immunization
coverage in children in LMICs. The review will address
the question of ‘which interventions work?’ and provide
some insight towards ‘how, why, and for whom these in-
terventions work?’.
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A logic model will be developed to help with scoping the
review, defining and conducting the review and making the
review relevant to policy and practice [10], using templates
developed as part of the EU-funded INTEGRATE-HTA
project (Anke Rohwer, personal communication).
We will also attempt to capture the complexity of the dif-
ferent interventions included in the review by assessing the
following domains proposed as part of a new tool devel-
oped within the Methodological Investigation of Cochrane
Reviews of Complex Interventions (MICCI) project (Simon
Lewin, personal communication): (1) number of discrete,
active components included in the intervention compared
with the control (or usual care); (2) number of behaviors or
actions of intervention recipients or participants to which
the intervention is directed; (3) number of organizational
levels targeted by the intervention; (4) degree of flexibility
or tailoring permitted across sites or individual intervention
implementation/application; (5) the level of skill required
by those delivering the intervention; and (6) the level of skill
required for the targeted behavior when entering the study
by those receiving the intervention (consumers, profes-
sionals, planners) in order to meet the intervention’s
objectives
Types of studies to be included
Intervention studies
RCTs, cluster randomized controlled trials (cRCTs),
NRCTs, interrupted time series studies (ITSs) and con-
trolled before-and-after studies (CBAs) will all be included.
Observational studies
Uncontrolled before-and-after studies, cohort studies,
case-control studies and cross-sectional studies will
qualify for inclusion.
Types of studies to be excluded
Supplementary immunization activities such as mass
campaigns and school-based immunization services will
be excluded.
Types of participants
Participants will include: children under 10 years of age
receiving WHO recommended vaccines through ‘routine
immunization services’, pregnant women receiving tet-
anus toxoid (TT) vaccination according to the national
immunization schedule, caregivers of children or preg-
nant women who are receiving the vaccines, healthcare
workers administering the vaccines and health facilities
or health programs providing immunization services.
Types of interventions
Interventions for improving routine immunization coverage
will be categorized in the following four groups, asimplemented in a previous systematic review [9]: (1)
patient-oriented or community-oriented interventions, (2)
provider-oriented interventions, (3) health-system interven-
tions, and (4) multifaceted interventions (unique combina-
tions of any of the above).
Outcomes
Primary outcome
The primary outcome will be the proportion of children
who have been fully immunized by the recommended
age according to the national immunization schedule, or
an appropriate proxy measure such as DTP3 coverage.
Secondary outcomes
Secondary outcomes will be identified from included stud-
ies. These may include, but are not limited to: (1) other
measures of immunization program performance as re-
ported by the authors, for example, coverage with a specific
vaccine, vaccine dropout rate, and adverse events following
immunization (AEFI); (2) occurrence of vaccine prevent-
able diseases (VPDs); (3) attitude and care-seeking behavior
of caregivers towards immunization; (4) attitude and skills
of healthcare workers; (5) characteristics of health facilities
or health programs providing immunization services;
(6) implementation of intervention; and (7) cost of
intervention.
Search strategy and sources
The following electronic databases will be searched for
peer-reviewed literature: Cochrane Database of Systematic
Reviews (CDSR), Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE published by 31
August 2013.
A comprehensive search strategy will be developed
that includes terms for immunization, coverage and
immunization programs; as well as terms for children. The
search strategy will be adapted to suit each individual data-
base using applicable controlled vocabulary (see Additional
file 1 for the proposed MEDLINE search strategy).
Data collection and analysis
Study selection
Two authors (SM and CSW) will screen titles and ab-
stracts of studies for potential eligibility. Following this,
full texts of potentially eligible studies will be retrieved.
Two authors (SM and CSW) will independently apply
inclusion criteria to identify relevant studies to be in-
cluded in the review. Any disagreements between the
two authors regarding study eligibility will be resolved
by discussion and consensus, failing which a third author
(ER, RvK or GDH) will arbitrate. We will provide a table
with characteristics of included studies, and another of
excluded studies with reasons for their exclusion, in the
final review.
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A data extraction form will be developed by consultation
and consensus among all authors. Two authors (SM and
CSW) will independently extract data and assess risk of bias
in included studies, compare their results, and resolve any
discrepancies by discussion and consensus. We plan to
analyze the data using Review Manager (RevMan).
Assessment of risk of bias
The quality of studies will be assessed using the modi-
fied GATE tool for experimental studies and the modi-
fied GATE tool for observational studies. Details of both
of these tools are provided in the updated NICE Public
Health Guidance manual for 2013 [11].
Two authors (SM and CSW) will apply the inclusion
criteria, and any disagreements will be resolved by dis-
cussion and consensus; failing which we will consult a
third author (ER, RvK or GDH).
Measures of treatment effect and data synthesis
We will express the result of each study as a risk ratio with
its corresponding 95% confidence intervals for dichotom-
ous data, or mean difference with its standard deviation for
continuous data. We will conduct meta-analysis for the
same type of participants, interventions, study designs, and
outcome measures where homogeneity of data allows. We
will use the random-effects model as the default procedure
for meta-analyses due to anticipated heterogeneity, even if
the latter is not statistically significant. If meta-analysis is
not feasible due to significant statistical heterogeneity, we
will explore the use of harvest plots. Harvest plots are a
novel method for synthesizing evidence about the differen-
tial effects of heterogeneous and complex interventions,
allowing review authors to maximize the learning potential
derived from the studies included, to tailor the characteris-
tics of studies that are most relevant within a particular
body of evidence, and to aid in visualizing the results [12].
Assessment of heterogeneity
We will assess statistical heterogeneity using the χ2 test
of homogeneity and quantify it using the I2 test statistic.
We will describe heterogeneity as high if the I2 test stat-
istic is greater than 50%, and will consider it statistically
significant if the P value for the χ2 test is ≤0.1. If studies
are found to be homogeneous (that is P value for the χ2
test is >0.1), results will be pooled by random effects
meta-analysis, stratified by study design. Subgroup ana-
lyses will be conducted where possible, with subgroups
defined by continent (Africa, Asia, Europe, Latin
America and the Caribbean), setting (for example, urban
vs rural), and vaccine delivery strategies. We will also
tabulate heterogeneity in context and implementation
between studies, using a new tool developed as partof the EU-funded INTEGRATE-HTA project (Lisa
Pfadenhauer, personal communication).Assessment of reporting bias
A funnel plot will be used to investigate the risk of pub-
lication bias by intervention type. The funnel plot will be
visually examined for asymmetry. Provided 10 or more
studies are included in the analysis for each intervention
type, we will use the Beggs-Egger test to assess for fun-
nel plot asymmetry.Sensitivity analyses
If there is sufficient data, we will conduct sensitivity ana-
lyses to assess the effects of missing data, study design, and
risk of bias on our primary meta-analyses. When we find a
study with missing data, we will first perform available cases
analysis; followed by sensitivity analyses according to impu-
tations (that is, from assuming that all missing data are fail-
ures to assuming that all missing data are successes). We
will also conduct sensitivity analyses to investigate the ro-
bustness of the results to study design (intervention vs cor-
relation), method of meta-analysis (that is, random effects
vs fixed effect), and risk of bias (that is, excluding studies
with high risk of bias).
This protocol has not been registered with PROSPERO.Discussion
Expected significance of the study
The findings of this extensive review will provide a dee-
per understanding of not only which interventions have
been shown to work for improving vaccination coverage
in LMICs, but provide insight on how they work, why
they work, and for whom these interventions work. The
review will allow us to document evidence across a
broad range of intervention types and also distinguish
between those that are well supported by evidence (to
direct policy recommendations) and those that are not
well supported (to direct research agenda). In addition,
understanding and documenting of study contextual fac-
tors will allow for greater understanding of external val-
idity through detailed assessment and facilitate better
replication of interventions in other locations.
With an estimated 22.4 million children reported to
not have received the DTP3 vaccine in 2011, where
more than 70% of these children live in 10 LMICs coun-
tries (Afghanistan, Chad, Democratic Republic of the
Congo, Ethiopia, India, Indonesia, Nigeria, Pakistan,
Philippines and South Africa), identifying effective inter-
ventions for improving vaccination coverage in LMICs
remains key in efforts to achieve universal childhood
immunization [4].
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